Key result
Extracorporeal membrane oxygenation support was associated with impaired platelet aggregation and decreased platelet activation on day 1 compared with healthy controls, with no marked difference in activation from day 1 to day 3.
Why the study?
Hemorrhagic and thromboembolic complications are common during ECMO support, prompting investigation into how ECMO affects platelet function.
Does extracorporeal membrane oxygenation (ECMO) support impair platelet function in adult patients with severe cardiac and/or pulmonary failure?
Cohort (n=33)
No
Does extracorporeal membrane oxygenation (ECMO) support impair platelet function in adult patients with severe cardiac and/or pulmonary failure?
p-value: p=>0.05
While absolute platelet aggregation and activation are reduced on day 1 of ECMO support compared to healthy controls, aggregation is not impaired when adjusted for the low platelet counts typically seen in these patients.
No takes yet. Share an insight, caveat, or question.
Altered platelet function during ECMO may increase bleeding risk; hypothesis-generating for function-guided therapy in prospective studies.
Balle et al. (2019) conducted a cohort in Severe cardiac and/or pulmonary failure requiring ECMO support (n=33). Extracorporeal membrane oxygenation (ECMO) vs. Healthy controls was evaluated on Difference in platelet activation from day 1 to day 3 on ECMO support measured by flow cytometry (p=>0.05). Extracorporeal membrane oxygenation support was associated with impaired platelet aggregation and decreased platelet activation on day 1 compared with healthy controls, with no marked difference in activation from day 1 to day 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: